Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone011-41-22-716-9800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.13 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Quotient (NASDAQ:QTNT) Frequently Asked Questions
What is Quotient's stock symbol?
Quotient trades on the NASDAQ under the ticker symbol "QTNT."
How were Quotient's earnings last quarter?
Quotient Ltd (NASDAQ:QTNT) announced its earnings results on Monday, August, 5th. The company reported ($0.36) EPS for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.03. The business had revenue of $8.17 million for the quarter, compared to the consensus estimate of $8.40 million. View Quotient's Earnings History.
When is Quotient's next earnings date?
What guidance has Quotient issued on next quarter's earnings?
Quotient issued an update on its second quarter 2020 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.3-6.7 million, compared to the consensus revenue estimate of $6.5 million.
What price target have analysts set for QTNT?
1 brokerages have issued 12 month target prices for Quotient's stock. Their predictions range from $13.50 to $13.50. On average, they anticipate Quotient's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for Quotient.
What is the consensus analysts' recommendation for Quotient?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.
Has Quotient been receiving favorable news coverage?
Headlines about QTNT stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quotient earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Quotient.
Who are some of Quotient's key competitors?
Some companies that are related to Quotient include Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Heska (HSKA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB), ImmuCell (ICCC), Celldex Therapeutics (CLDX) and Riot Blockchain (RIOT).
What other stocks do shareholders of Quotient own?
Who are Quotient's key executives?
Quotient's management team includes the folowing people:
- Mr. Franz Walt, CEO & Director (Age 60)
- Mr. Jeremy Stackawitz, Pres (Age 44)
- Mr. Edward Farrell, Pres (Age 49)
- Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
- Mr. John Allan, Corp. Sr. VP & CTO
Who are Quotient's major shareholders?
Quotient's stock is owned by a number of of institutional and retail investors. Top institutional investors include Cormorant Asset Management LP (5.73%), Highbridge Capital Management LLC (2.99%), Morgan Stanley (2.83%), Allianz Asset Management GmbH (1.06%), JPMorgan Chase & Co. (0.46%) and Point72 Asset Management L.P. (0.36%). Company insiders that own Quotient stock include Brian Mcdonough, D J Paul E Cowan, Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive and Prondzynski Heino Von. View Institutional Ownership Trends for Quotient.
Which major investors are selling Quotient stock?
QTNT stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Highbridge Capital Management LLC, D. E. Shaw & Co. Inc., Ardsley Advisory Partners LP and LPL Financial LLC. Company insiders that have sold Quotient company stock in the last year include Edward Farrell and Jeremy Stackawitz. View Insider Buying and Selling for Quotient.
Which major investors are buying Quotient stock?
QTNT stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Morgan Stanley, Swiss National Bank, Allianz Asset Management GmbH, BlackRock Inc., Bank of New York Mellon Corp, Point72 Asset Management L.P. and Jane Street Group LLC. Company insiders that have bought Quotient stock in the last two years include Brian Mcdonough, Frederick Hallsworth, Life Sciences Maste Perceptive and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.
How do I buy shares of Quotient?
Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quotient's stock price today?
One share of QTNT stock can currently be purchased for approximately $11.03.
How big of a company is Quotient?
Quotient has a market capitalization of $730.96 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. View Additional Information About Quotient.
What is Quotient's official website?
How can I contact Quotient?
Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.
MarketBeat Community Rating for Quotient (NASDAQ QTNT)
MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote "Outperform" if you believe QTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
